Amalgamated Bank’s Relmada Therapeutics RLMD Stock Holding History

Amalgamated Bank’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,552	Closed	-$8K	–	3108
2023 Q1	$8K	Sell	3,552 -592	-14%	-$2.04K	﹤0.01%	2850
2022 Q4	$14K	Hold	4,144	–	–	﹤0.01%	2827
2022 Q3	$153K	Buy	4,144 +49	+1%	+$1.36K	﹤0.01%	1955
2022 Q2	$78K	Buy	4,095 +528	+15%	+$11.5K	﹤0.01%	2281
2022 Q1	$96K	Buy	+3,567	New	+$73.8K	﹤0.01%	2213

Other funds holding RLMD

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

Amalgamated Bank's RLMD Position: Q2 2023 in Review

Amalgamated Bank sold out of Relmada Therapeutics (RLMD) in Q2 2023, closing a stake of 3,552 shares — an estimated $8K sold.

Amalgamated Bank first reported a position in RLMD in Q1 2022 and held it in 5 quarters. The position peaked at $153K in Q3 2022. 95 funds tracked by Wall St. Rank hold RLMD as of Q2 2023.

Amalgamated Bank reported no remaining Relmada Therapeutics position as of Q2 2023 after selling out during the quarter.
Amalgamated Bank sold 3,552 Relmada Therapeutics shares in Q2 2023, an estimated $8K.
Amalgamated Bank first reported a position in Relmada Therapeutics in Q1 2022 and held it in 5 quarters.
Amalgamated Bank's Relmada Therapeutics position peaked at $153K in Q3 2022.
95 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2023.

Based on Amalgamated Bank's 13F filing for Q2 2023, filed 11 Aug 2023.